NEW YORK, July 26, 2024 /PRNewswire/ -- The
global motion sickness drugs market size is estimated to
grow by USD 139.5 million from
2024-2028, according to Technavio. The market is estimated to grow
at a CAGR of 4.37% during the forecast period. availability of
over-the-counter (OTC) drugs is driving market growth, with a trend
towards advent of nauseogenic information technology.
However, nonpharmacological countermeasures to treat motion
sickness poses a challenge. Key market players include Abbott
Laboratories, Amneal Pharmaceuticals Inc., Baxter
International Inc., CVS Health Corp., DM Pharma Marketing Pvt.
Ltd., GlaxoSmithKline Plc, Hylands, Lupin Ltd., Merck KGaA,
Myungmoon Pharm Co. Ltd., Novartis AG, Perrigo Co. Plc, Prestige
Consumer Healthcare Inc., Sun Pharmaceutical Industries Ltd., Teva
Pharmaceutical Industries Ltd., Tivic Health Systems Inc., Viatris
Inc., WellSpring Pharmaceutical Corp., Zenomed Healthcare Pvt.
Ltd., and Zydus Lifesciences Ltd..
![Technavio has announced its latest market research report titled Global motion sickness drugs market 2024-2028 Technavio has announced its latest market research report titled Global motion sickness drugs market 2024-2028](https://mma.prnewswire.com/media/2469135/Technavio_Global_motion_sickness_drugs_market.jpg)
Get a detailed analysis on regions, market
segments, customer landscape, and companies - Click for the
snapshot of this report
Forecast
period
|
2024-2028
|
Base Year
|
2023
|
Historic
Data
|
2018 - 2022
|
Segment
Covered
|
Product (Antihistamines
and Anticholinergics), Distribution Channel (Offline and Online),
and Geography (North America, Europe, Asia, and Rest of World
(ROW))
|
Region
Covered
|
North America, Europe,
Asia, and Rest of World (ROW)
|
Key companies
profiled
|
Abbott Laboratories,
Amneal Pharmaceuticals Inc., Baxter International Inc., CVS Health
Corp., DM Pharma Marketing Pvt. Ltd., GlaxoSmithKline Plc, Hylands,
Lupin Ltd., Merck KGaA, Myungmoon Pharm Co. Ltd., Novartis AG,
Perrigo Co. Plc, Prestige Consumer Healthcare Inc., Sun
Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries
Ltd., Tivic Health Systems Inc., Viatris Inc., WellSpring
Pharmaceutical Corp., Zenomed Healthcare Pvt. Ltd., and Zydus
Lifesciences Ltd.
|
Key Market Trends Fueling Growth
Motion sickness is a common issue that restricts individuals
from traveling comfortably. Current treatments for motion sickness
are unsatisfactory, but recent advancements in brain imaging,
neuron physiology, and neuropharmacology offer potential solutions.
Neurophysiology, pathway mapping, and MRI techniques have been
employed to study the brain's cortex, cerebellum, and brainstem,
revealing the environmental and behavioral factors that trigger and
protect against motion sickness. Nauseogenic information
technology, which uses nausea-inducing vehicles to analyze postural
stability, has shown that motion sickness occurs at specific
frequencies. This technology is still in its infancy, but it's
expected to provide valuable insights for developing effective
motion sickness drugs. The nauseogenic information technology's
potential impact on the market is significant, as it could lead to
the discovery of new targets for motion sickness
medication.
Motion sickness, a temporary medical condition caused by
multi-axial motion or acceleration, results in discomfort and
sensation of nausea, increased salivation, belching, sweating, and
hyperventilation. Unmet healthcare needs persist due to the
distressing symptoms, particularly for pregnant women, children,
cancer patients, and travelers. Pharmacological therapies,
including antihistaminic drugs like Dimenhydrinate, Meclizine, and
Anticholinergics such as Prochlorperazine and Scopolamine, are
commonly used. Oral medications are available at hospital
pharmacies and online providers. New innovations like Reliefband
and Reliefband Sport provide non-pharmacological relief. The
COVID-19 pandemic and virtual reality technology have increased the
demand for motion sickness treatments. Females, pregnant women, and
those experiencing motion sickness in the US Virgin Islands are
among the significant consumer groups.
Discover 360° analysis of this market. For
complete information, schedule your consultation- Book
Here!
Market Challenges
- Motion sickness, a condition characterized by nausea, vomiting,
and dizziness caused by conflicting sensory signals, affects
individuals during travel or exposure to motion stimuli. Two
nonpharmacological countermeasures, habituation training and
behavioral training, are effective in preventing and controlling
motion sickness. Habituation training involves exposing individuals
to prolonged periods of motion stimulation to induce motion
sickness habituation. This method, which may last for several
weeks, stimulates sensory conflict in the brain to achieve
habituation. Parabolic flight, horizontal suspension, neural
buoyancy stimulation, and preflight virtual reality training are
examples of habituation training techniques used to prevent motion
sickness in astronauts and others. Behavioral training, on the
other hand, helps individuals balance visual and vestibular
information during motion sickness. A forward-looking vision to a
distant horizon, controlled breathing, soothing music, and odor are
some behavioral measures that alleviate motion sickness symptoms.
Additionally, a protein-rich beverage taken before optokinetic
stimulation and vitamin C supplementation have proven effective in
treating motion sickness. Traditional Chinese practices, such as
acupuncture at P6 or Nei guan point and transcutaneous electrical
nerve stimulation of the right Zusanli acupoint and the posterior
neck, have also been used to suppress motion sickness symptoms and
alleviate cognitive impairment. These nonpharmacological
countermeasures are crucial in controlling and preventing motion
sickness, reducing the need for pharmacological drugs.
- Motion sickness, characterized by belching, sweating,
hyperventilating, and an uncomfortable sensation, affects various
populations including travelers, cancer patients, and those using
virtual reality technology. Pharmacological therapies offer relief
through antihistaminic and anticholinergic drugs. Antihistamines
like dimenhydrinate, meclizine, and anticholinergics such as
scopolamine and prochlorperazine are common treatments. Oral
medications are widely used, but transdermal drugs like the
Scopolamine patch offer advantages. In developed economies, demand
for motion sickness drugs is high, particularly in hospital
pharmacies and online providers. The COVID-19 pandemic has
increased demand due to travel restrictions. Wearable relief bands
like Reliefband and Reliefband Sport are gaining popularity.
Traditional medicines also play a role in motion sickness
treatment. The route of administration and availability through
various channels, including prescription drugs, online pharmacies,
drug stores, and retail pharmacies, impact market dynamics.
For more insights on driver and
challenges - Download a Sample Report
Segment Overview
This motion sickness drugs market report extensively covers
market segmentation by
- Product
- 1.1 Antihistamines
- 1.2 Anticholinergics
- Distribution Channel
- Geography
- 3.1 North America
- 3.2 Europe
- 3.3 Asia
- 3.4 Rest of World (ROW)
1.1 Antihistamines- The Motion Sickness Drugs
Market is primarily served by first-generation antihistamines,
including Cinnarizine, Meclizine, Promethazine hydrochloride, and
Promethazine teoclate. These drugs possess anti-allergic,
anti-tussive, anti-pruritic, and anti-emetic properties. Their
anti-emetic effect is attributed to the blockade of histamine 1
(H1) receptors and muscarinic receptors. Cinnarizine, a piperazine
derivative, takes effect two to three hours post-administration,
with a half-life of three to six hours. Meclizine hydrochloride,
another piperazine, has the least sedative effect and a longer
duration of action. Promethazine hydrochloride and promethazine
teoclate, phenothiazines, are widely used for nausea, vomiting, and
vertigo treatment, with marketed anti-motion sickness activity and
sedative effects. Cyclizine, an approved motion sickness treatment,
is subjected to abuse due to its euphoric effect and is available
over-the-counter (OTC). The OTC availability of these drugs
increases accessibility and affordability, making them popular
choices for preventing and treating motion sickness. The
first-generation antihistamines' anti-motion sickness activity is
not solely due to histamine blockade but rather their peripheral-
and central-acting anticholinergic properties. As such, their
widespread use among motion sickness patients is expected to fuel
market growth throughout the forecast period.
For more information on market segmentation with geographical
analysis including forecast (2024-2028) and historic data (2018 -
2022) - Download a Sample Report
Learn and explore more about Technavio's in-depth research
reports
The Information Technology (IT) market in Chile is rapidly expanding, driven by
increased digital transformation and technological adoption, with
significant growth projected in cloud computing and cybersecurity
sectors. Meanwhile, the global antiemetic drug market is fueled by
rising cancer treatments and nausea-related conditions.
Additionally, the global diuretic drugs market is anticipated to
grow due to the increasing prevalence of hypertension and heart
failure.
Research Analysis
Motion sickness, a temporary sensation of discomfort and anxiety
caused by multi-axial motion, acceleration, and sensory conflict
between the eyes and inner ear, is a common medical condition
affecting millions globally. Unmet healthcare needs persist due to
the varying severity and triggers of motion sickness, including
travel, virtual reality, and certain medical conditions like cancer
and Coronavirus. Medicines, including prescription drugs and
traditional remedies, are used for relief. Developed economies
witness high demand dynamics for motion sickness drugs, with
wearable relief bands like Reliefband and Reliefband Sport gaining
popularity. Transdermal drugs and oral drugs are common routes of
administration, while online pharmacies offer convenient access to
these medicines. Motion sickness affects travelers, females, and
individuals undergoing cancer treatment, highlighting the need for
effective and accessible solutions. Acetylcholine plays a key role
in the development of motion sickness, making it a target for drug
development.
Market Research Overview
Motion sickness is a common medical condition characterized by
temporary sensation of discomfort, nausea, anxiety, and other
symptoms caused by multi-axial motion, acceleration, and sensory
conflict between the eyes and inner ear. Unmet healthcare needs for
motion sickness relief are significant, particularly for pregnant
women, children, cancer patients, travelers, and individuals
experiencing virtual reality or coronavirus-related motion
sickness. Pharmacological therapies include antihistaminic drugs,
such as dimenhydrinate, meclizine, and diphenhydramine, and
anticholinergic drugs, like scopolamine and prochlorperazine. These
drugs come in various forms, including oral medications,
transdermal patches, and wearable relief bands like Reliefband and
Reliefband Sport. Healthcare systems, hospital pharmacies, online
providers, drug stores, and retail pharmacies offer these medicines
for relief. Symptoms of motion sickness include nausea, increased
salivation, belching, sweating, hyperventilating, and an
uncomfortable sensation in the stomach. In developed economies,
demand dynamics for motion sickness treatments continue to grow,
with traditional medicines and prescription drugs also playing a
role in the market.
Table of Contents:
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation
- Product
-
- Antihistamines
- Anticholinergics
- Distribution Channel
-
- Geography
-
- North America
- Europe
- Asia
- Rest Of World (ROW)
7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Trends
10 Company Landscape
11 Company Analysis
12 Appendix
About Technavio
Technavio is a leading global technology research and advisory
company. Their research and analysis focuses on emerging market
trends and provides actionable insights to help businesses identify
market opportunities and develop effective strategies to optimize
their market positions.
With over 500 specialized analysts, Technavio's report library
consists of more than 17,000 reports and counting, covering 800
technologies, spanning across 50 countries. Their client base
consists of enterprises of all sizes, including more than 100
Fortune 500 companies. This growing client base relies on
Technavio's comprehensive coverage, extensive research, and
actionable market insights to identify opportunities in existing
and potential markets and assess their competitive positions within
changing market scenarios.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/
View original content to download
multimedia:https://www.prnewswire.com/news-releases/motion-sickness-drugs-market-size-is-set-to-grow-by-usd-139-5-million-from-2024-2028--availability-of-over-the-counter-otc-drugs-to-boost-the-market-growth-technavio-302206564.html
SOURCE Technavio